Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | ACHE | P22303 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.41 |
| ▸ | TP53 | P04637 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | MGLL | Q99685 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4752093 | 0.86 | ALDH1A1 (0.44) | L3MBTL1ALDH1A1LMNAMAPTSMN1; SMN2 | |
| SCHEMBL4301380 | 0.85 | SMN1; SMN2 (0.46) | POLBALDH1A1CYP2C19LMNAMAPT | |
| SCHEMBL4301342 | 0.85 | ALDH1A1 (0.42) | POLBALDH1A1CYP2C19MAPTSMN1; SMN2 | |
| SCHEMBL4298277 | 0.85 | KDM4E (0.45) | POLBALDH1A1CYP2C19LMNAMAPT | |
| SCHEMBL4292826 | 0.84 | ALDH1A1 (0.50) | L3MBTL1POLBALDH1A1CYP2C19MAPT | |
| SCHEMBL4294973 | 0.84 | MGLL (0.40) | L3MBTL1POLBALDH1A1CYP2C19LMNA | |
| SCHEMBL4753498 | 0.83 | ALDH1A1 (0.48) | L3MBTL1POLBALDH1A1CYP2C19MAPT | |
| SCHEMBL4298297 | 0.83 | MGLL (0.46) | POLBALDH1A1CYP2C19MAPTMGLL | |
| SCHEMBL4293508 | 0.80 | ALDH1A1 (0.42) | POLBALDH1A1CYP2C19MAPTSMN1; SMN2 | |
| SCHEMBL4288263 | 0.80 | NPSR1 (0.43) | L3MBTL1POLBALDH1A1CYP2C19LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090227560-A1 | Substituted imidazole compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-09-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090227560-A1 | Substituted imidazole compound and use thereof | REN, ACE, AGT | L3MBTL1 3597/4885POLB 3799/4885ALDH1A1 388/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.